Literature DB >> 21860222

Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors.

Virginie Simon-Blancal1, Olivia Freynet, Hilario Nunes, Diane Bouvry, Nicolas Naggara, Pierre-Yves Brillet, Damien Denis, Yves Cohen, François Vincent, Dominique Valeyre, Jean-Marc Naccache.   

Abstract

BACKGROUND: Acute exacerbation is a substantial cause of death in patients with idiopathic pulmonary fibrosis with poorly described prognostic factors.
OBJECTIVES: To review the features associated with acute exacerbation of idiopathic pulmonary fibrosis and assess its prognostic factors.
METHODS: Thirty-seven occurrences of acute exacerbation of idiopathic pulmonary fibrosis were retrospectively reviewed in the medical records of 27 patients. Clinical presentation, radiographic studies, pulmonary function tests, laboratory data, treatment, and outcome were analyzed.
RESULTS: Acute exacerbation of idiopathic pulmonary fibrosis occurred more frequently between December and May (75.7%) than between June and November (24.3%) (p = 0.01). In-hospital mortality was 27% and median survival was 4.2 months (range 0.2-36.6). Significant differences between nonsurvivors and survivors included the time elapsed between their admission and the initiation of treatment for acute exacerbation (6 vs. 3.1 days, p = 0.04), lactate dehydrogenase levels at admission (801 vs. 544.6 IU/l, p = 0.002), impairment of the prior forced vital capacity (51.2 vs. 65%, p = 0.01) and diffusing capacity for carbon monoxide (21.7 vs. 34%, p = 0.01). Furthermore, the evolution of gas exchange in the first 10 days after the initiation of treatment was associated with in-hospital and long-term mortality.
CONCLUSIONS: Acute exacerbations of idiopathic pulmonary fibrosis are more frequent during winter and spring. The time between admission and initiation of treatment is a new reported prognostic factor that should be investigated further. This finding highlights the need for a fast diagnostic approach that should probably be standardized. Early gas exchange modifications reflect the response to treatment and predict the prognosis.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21860222     DOI: 10.1159/000329891

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  47 in total

1.  Acute exacerbation of idiopathic interstitial pneumonia after nonpulmonary surgery under general anesthesia: a retrospective study.

Authors:  Kenta Furuya; Susumu Sakamoto; Yujiro Takai; Nobukazu Sato; Keiko Matsumoto; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Authors:  Kerri Johannson; Harold R Collard
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 4.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 5.  Recipient selection process and listing for lung transplantation.

Authors:  Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Takefumi Nikaido; Yoshinori Tanino; Xintao Wang; Yuki Sato; Ryuichi Togawa; Masami Kikuchi; Kenichi Misa; Kazue Saito; Naoko Fukuhara; Takaya Kawamata; Mami Rikimaru; Takashi Umeda; Julia Morimoto; Tatsuhiko Koizumi; Yasuhito Suzuki; Kenichiro Hirai; Manabu Uematsu; Hiroyuki Minemura; Atsuro Fukuhara; Suguru Sato; Junpei Saito; Hiroshi Yokouchi; Kenya Kanazawa; Yoko Shibata
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

7.  Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.

Authors:  Tejaswini Kulkarni; Steven R Duncan
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

8.  Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation.

Authors:  Ryo Yamazaki; Osamu Nishiyama; Sho Saeki; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

9.  Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease.

Authors:  Colin J Adams; Karan Chohan; Dmitry Rozenberg; John Kavanagh; Gerhard Greyling; Shane Shapera; Jolene H Fisher
Journal:  Lung       Date:  2021-08-04       Impact factor: 2.584

10.  Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Nobuyasu Awano; Taisuke Jo; Hideo Yasunaga; Minoru Inomata; Naoyuki Kuse; Mari Tone; Kojiro Morita; Hiroki Matsui; Kiyohide Fushimi; Takahide Nagase; Takehiro Izumo
Journal:  ERJ Open Res       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.